Pharma: action, reaction and insight – the week to February 10, 2023

By Barbara Obstoj-Cardwell. Editor

At the start of last week, US pharma major Bristol Myers Squibb pulled out of a licensing collaboration with Dragonfly Therapeutics on the development of the latter’s cancer drug candidate DF6002. UK pharma major GSK gained US Food and Drug Administration for its immune-oncology drug Jemperli for the treatment of endometrial cancer and an FDA advisory committee voted in favor of a clinical trial testing the drug in rectal cancer. There were a number of financial results releases, among which Anglo-Swedish drugmaker AstraZeneca posted fourth-quarter and full-year 2022 figures claiming that long-term investment in R&D is paying off. Also, the USA’s AbbVie announced financials on Thursday, with full-year guidance that warned its best-selling drug Humira will now be facing biosimilar competition in the USA.

Bristol Myers’ exit clips Dragonfly’s wings